Results 221 to 230 of about 2,769,024 (292)

Censorship in science: How publishing decisions could have shaped the perceived "general consensus" on COVID-19 vaccine safety and efficacy. [PDF]

Oncotarget
Polykretis P, Lindsay JC, Gentilini P, Konishi N, Fukushima M.   +4 more
europepmc   +1 more source

Ferritin as a Nanoparticle Scaffold for Plant‐Produced Next‐Generation Subunit Vaccines

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Protein nanoparticles offer an innovative approach to next‐generation subunit vaccine development by displaying antigenic sequences on the nanoparticle surface. Compared to traditional subunit vaccines, protein nanoparticle vaccines often show improved interaction with the immune system due to their particulate size and repetitive epitope ...
Jordan T. VanderBurgt, Richard Strasser, Christopher P. Garnham, Rima Menassa   +3 more
wiley   +1 more source

RSV Vaccination Programme for Older Adults: A Scotland-Wide Study on RSVpreF Vaccine Safety. [PDF]

Vaccines (Basel)
Cullen LA, Gibbons CL, Shi T, Hasan T, Sullivan C, Marsh K, Robertson C, Cameron JC, Ghebrehewet S.   +8 more
europepmc   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Statistical Methods for Multi-jurisdictional Australian Vaccine Safety Investigations of Rare Adverse Events. [PDF]

Drug Saf
Morgan HJ, Bloomfield L, Clothier HJ, Ngeh S, Cadby G, Carcione D, Boyd JH, Kattan GS, Buttery JP, Effler P.   +9 more
europepmc   +1 more source

Purification of Disassembled Capsid Protein by Hydroxyapatite Chromatography Enhances Virus‐Like Particle Recovery

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer.
Nicholas Samuelson, Nathaniel Parker, Shiyi Wang, Sara Daley, Aaron Cote, Michael A. Winters   +5 more
wiley   +1 more source

JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States. [PDF]

Infection
Duffy J, Yih WK, Walton K, DeSilva MB, Glanz JM, Hambidge SJ, Jackson LA, Klein NP, Lewin BJ, Naleway AL, Sundaram ME, Maro JC, Weintraub E.   +12 more
europepmc   +1 more source

Mechanistic Digital Model for Real‐Time Monitoring and Optimization of Adenovirus Production

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Adenoviral vectors are a critical vaccine platform, with billions of vaccine doses administered during the COVID‐19 pandemic. In addition, they are promising therapeutics for cancer treatment. To advance their manufacturing, real‐time monitoring of adenovirus production is essential for process optimization, yield improvement, and product ...
Xingge Xu, Daniel Rüdiger, Jeongbin Shin, Shawninder Chahal, Amine Kamen   +4 more
wiley   +1 more source

Cohort event monitoring of booster COVID-19 vaccine safety using patient-reported outcomes in pregnant women. [PDF]

Front Drug Saf Regul
Maisonneuve E, Luxi N, Bellitto C, Ciccimarra F, Raethke M, van Hunsel F, Lieber T, Mulder E, Riefolo F, Villalobos F, Thurin NH, Batel-Marques F, Morton K, O'Shaughnessy F, Cleary B, Sonderlichová S, Farcas A, Bucsa C, Favre G, Siiskonen SJ, Baud D, Sturkenboom MCJM, Trifirò G, Panchaud A.   +23 more
europepmc   +1 more source

Efficient Cell Removal and Impurity Reduction for Poxvirus Purification in a Single Step Alluvial Filtration

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Modified Vaccinia virus Ankara (MVA) is a potent vector for the development of vaccines and novel cancer treatment strategies. Since it is a non‐replicating virus in human recipients, high infective titers are required for therapeutic efficacy.
Linus G. Weber, Caroline Stephan, Georgios Makris, Leander John, Ingo Jordan, Michael W. Wolff   +5 more
wiley   +1 more source